Vimta Labs Ltd Stock Analysis

BSE: 524394 | NSE: VIMTALABS | Miscellaneous | Small Cap

BSE Share Price 23-Sep-2022 18:01
344.85 4.65 (1.37%)

DeciZen - Make an Informed Decision on Vimta Labs

Overall Rating

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Semi Strong

Vimta Labs Price Chart

P/E Ratio (SA) :
16.95
Market Cap :
762.4 Cr.
52-wk low :
270
52-wk high :
453
Bole Toh?

1. Is Vimta Labs Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Vimta Labs Ltd is a average quality company.

2. Is Vimta Labs Ltd undervalued or overvalued?

The key valuation ratios of Vimta Labs Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Vimta Labs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Vimta Labs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Vimta Labs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Vimta Labs Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 4.5%10.8%4.2%5.2%7.5%10.9%14.4%4.2%10.8%18.1%-
Value Creation Index -0.7-0.2-0.7-0.6-0.5-0.20.0-0.7-0.20.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 109118107125154183213181209276294
YoY Gr. Rt. %-8.5%-9.3%16.3%23.4%19.2%15.9%-15%15.7%32%-
Adj EPS 1.75.42.22.957.511.32.69.81920.4
YoY Gr. Rt. %-211%-59.3%31.5%71.9%51.9%49.7%-76.7%272.1%95%-
BVPS (₹) 50.854.555.35761.668.877.678.287.9104.4109.8
Adj Net Profit 3.811.94.86.410.916.624.95.821.64245
Cash Flow from Ops. 15.516.815.3-123.933.439.324.43758.7-
Debt/CF from Ops. 0.80.40.2-25.61.81.20.71.30.80.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.9%12.4%9.1%32%
Adj EPS 30.5%30.9%19.1%95%
BVPS 8.311.110.418.8
Share Price 34.8% 21.7% 49.5% 22.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 3.510.245.18.311.515.43.411.719.619
Op. Profit Mgn % 192216.215.218.124.827.216.625.42929.6
Net Profit Mgn % 3.510.14.55.17.19.111.73.210.315.215.3
Debt to Equity 0.10.100.20.30.30.20.20.20.1-
Working Cap Days 1661571871991871681581951861580
Cash Conv. Cycle 78861121189992101128113950

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 19.00%

Net Profit is growing at healthy rate in last 3 years 19.07%

Sales growth is good in last 4 quarters at 23.58%

Sales growth has been subdued in last 3 years 9.08%

Latest Financials - Vimta Labs Ltd.

Standalone Consolidated
TTM EPS (₹) 20.4 20.5
TTM Sales (₹ Cr.) 294 296
BVPS (₹.) 109.8 110
Reserves (₹ Cr.) 238 239
P/BV 3.14 3.14
PE 16.95 16.84
From the Market
52 Week Low / High (₹) 270.00 / 453.00
All Time Low / High (₹) 0.20 / 453.00
Market Cap (₹ Cr.) 762
Equity (₹ Cr.) 4.4
Face Value (₹) 2
Industry PE 30.6

Management X-Ray of Vimta Labs :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Vimta Labs

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

About Vimta Labs Ltd

Vimta Labs is India’s leading contract research and testing organization. Established in 1984, Vimta has an envious track record of serving several market leaders across the globe.

Vimta supports regulatory authorities in mandatory certification of food and agri products exported from India. Vimta assists the food industry commissions for nutritional labelling, food safety evaluations, trace analysis and shelf life studies.

Vimta has a team of 684 professionals comprising 446 scientists in various disciplines such as chemistry, pharma, medicine, microbiology, molecular biology and informatics. The team is slated to double in next three years.

Vimta is a multi-site organization with more than 300,000 sqft world class laboratory facilities. The technologies deployed at Vimta are current and leading edge, duly validated.

Vimta has over 12 years of experience in providing preclinical services to Pharma companies world-wide accordance with the guidelines prescribed by international agencies.

Vimta has a state-of-art building of Class 10,000 Pre-clinical facility with a total built up area of 33,000 sq.ft. with 32 rodent experimental rooms, 5 procedure rooms, separate quarantine facility and distinct non-rodent facility with 48 SS kennels with a comfortable perch, liberal exercise area.

It provides services in pharmacology, toxicology and DMPK areas. The toxicology services include but not limited to in-vivo and in-vitro genotoxicity, acute to chronic toxicity, carcinogenicity, reproductive toxicity studies, safety pharmacology, and immunotoxicology. Pharmacology services are available in various therapeutics areas such as pain & inflammation, metabolic disorders, respiratory, CNS, and xenograft & allograft models for oncology. In addition to the regulatory studies we use tailor-made in vitro and in vivo ADME techniques to help profile your drug candidate in both rodent and non-rodent animals models.

Services offered by the company:

  • Advanced Molecular Biology
  • Food and Agriculture
  • Drugs & Pharma
  • Water
  • Environmental Assessments
  • Clinical Research
  • Clinical Reference Lab Services
  • Preclinical Research
  • Genomics Online Ordering

 Achievements/ recognition

  •    NABL as per ISO 15189:2007
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now